CN1269844C - 壳聚糖衍生物及其制备方法与在制药中的应用 - Google Patents
壳聚糖衍生物及其制备方法与在制药中的应用 Download PDFInfo
- Publication number
- CN1269844C CN1269844C CNB031129811A CN03112981A CN1269844C CN 1269844 C CN1269844 C CN 1269844C CN B031129811 A CNB031129811 A CN B031129811A CN 03112981 A CN03112981 A CN 03112981A CN 1269844 C CN1269844 C CN 1269844C
- Authority
- CN
- China
- Prior art keywords
- chitosan
- chain alkyl
- sulfonic group
- preparation
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 44
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 229940079593 drug Drugs 0.000 title claims description 12
- 229920002101 Chitin Polymers 0.000 title 1
- 229920001661 Chitosan Polymers 0.000 claims abstract description 133
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 23
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 23
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 23
- 229930105110 Cyclosporin A Natural products 0.000 claims abstract description 19
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 19
- 239000000693 micelle Substances 0.000 claims abstract description 15
- 229920000642 polymer Polymers 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 238000003756 stirring Methods 0.000 claims description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 238000006467 substitution reaction Methods 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 18
- 238000000502 dialysis Methods 0.000 claims description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 230000006196 deacetylation Effects 0.000 claims description 9
- 238000003381 deacetylation reaction Methods 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 claims description 9
- -1 alkyl aldehyde Chemical class 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000003808 methanol extraction Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000890 drug combination Substances 0.000 claims description 2
- 206010018910 Haemolysis Diseases 0.000 abstract description 31
- 231100000419 toxicity Toxicity 0.000 abstract description 7
- 230000001988 toxicity Effects 0.000 abstract description 7
- 238000010253 intravenous injection Methods 0.000 abstract description 2
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 230000007928 solubilization Effects 0.000 abstract 1
- 238000005063 solubilization Methods 0.000 abstract 1
- 230000008588 hemolysis Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 12
- 239000002994 raw material Substances 0.000 description 11
- 230000002209 hydrophobic effect Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 239000003937 drug carrier Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- LKAPTZKZHMOIRE-KVTDHHQDSA-N (2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbaldehyde Chemical class OC[C@H]1O[C@H](C=O)[C@@H](O)[C@@H]1O LKAPTZKZHMOIRE-KVTDHHQDSA-N 0.000 description 7
- 238000005374 membrane filtration Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000002949 hemolytic effect Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- 231100000403 acute toxicity Toxicity 0.000 description 4
- 230000007059 acute toxicity Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000008676 import Effects 0.000 description 4
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229920000578 graft copolymer Polymers 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000003307 reticuloendothelial effect Effects 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000012412 chemical coupling Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- HFJRKMMYBMWEAD-UHFFFAOYSA-N dodecanal Chemical compound CCCCCCCCCCCC=O HFJRKMMYBMWEAD-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940089454 lauryl aldehyde Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002539 nanocarrier Substances 0.000 description 2
- 229960000715 nimodipine Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- 229960000641 zorubicin Drugs 0.000 description 2
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
受试品剂量mg/kg | 动物数(只) | 每天动物死亡数(只) | |||||||||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14(天) | ||
500400320256204.8 | 1010101010 | 44000 | 62210 | 01011 | 00100 | 00110 | 00000 | 00000 | 00000 | 00000 | 00000 | 00000 | 00000 | 00000 | 00000 |
受试品剂量mg/kg | 对数剂量(x) | 动物数(只) | 死亡动物数(只) | 死亡率(%) | 机率单位(Y) | LD50值及95%可信限(mg/kg) |
500400320256204.8 | 2.6992.6022.5052.4082.311 | 1010101010 | 107431 | 10070403010 | 6.8655.5134.7504.4863.729 | 315.69(276.48~360.47) |
试管编号 | 1 | 2 | 3 | 4 | 5 | 6 |
2%红细胞混悬液(ml) | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
生理盐水(ml) | 2.0 | 2.1 | 2.2 | 2.3 | 2.4 | 2.5 |
37℃ | 恒温 | 半小时 | ||||
药液(ml) | 0.5 | 0.4 | 0.3 | 0.2 | 0.1 | 0 |
37℃ | 恒温 | 4小时 | ||||
2000rpm,5min,540nm测定吸收度 |
试管编号 | 1 | 2 | 3 | 4 | 5 | 6 |
载体10mg/ml3mg/ml1mg/ml | 溶血部分溶血未溶血 | 溶血部分溶血未溶血 | 溶血部分溶血未溶血 | 部分溶血未溶血未溶血 | 部分溶血未溶血未溶血 | 未溶血未溶血未溶血 |
载体浓度(g/100ml) | 紫杉醇(μg/ml) | 环孢素A(μg/ml) | ||||
透析法 | 挥发法 | 搅拌法 | 透析法 | 挥发法 | 搅拌法 | |
0.5680.5540.2520.063 | 201019501540120 | 556503321230 | 3423118 | 57554716 | 2623145 | 9741 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031129811A CN1269844C (zh) | 2003-03-14 | 2003-03-14 | 壳聚糖衍生物及其制备方法与在制药中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031129811A CN1269844C (zh) | 2003-03-14 | 2003-03-14 | 壳聚糖衍生物及其制备方法与在制药中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1439655A CN1439655A (zh) | 2003-09-03 |
CN1269844C true CN1269844C (zh) | 2006-08-16 |
Family
ID=27796934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031129811A Expired - Fee Related CN1269844C (zh) | 2003-03-14 | 2003-03-14 | 壳聚糖衍生物及其制备方法与在制药中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1269844C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108273039A (zh) * | 2015-12-16 | 2018-07-13 | 新乡医学院第附属医院 | 一种治疗溶血性贫血的药物组合物及其应用 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100572388C (zh) * | 2005-12-14 | 2009-12-23 | 河南省科学院河南省发展计划委员会地理研究所 | 乙酰水杨酸与壳聚糖-2,6位接枝物制备方法 |
CN100450549C (zh) * | 2006-01-16 | 2009-01-14 | 中国药科大学 | 一种药物增溶载体及其制备方法和应用 |
CN101396563B (zh) * | 2008-11-06 | 2011-06-29 | 中国药科大学 | 以奥曲肽为靶向配基的壳聚糖衍生物及其在药剂中的应用 |
CN102477107B (zh) * | 2010-11-29 | 2013-10-09 | 中国药科大学 | 一种甘露糖化壳聚糖的制备方法 |
CN106964299A (zh) * | 2017-03-21 | 2017-07-21 | 大连理工大学 | 一种高稳定性溢油分散剂及其制备方法 |
CN107383239B (zh) * | 2017-08-28 | 2019-06-25 | 中国科学院烟台海岸带研究所 | 一种n-吡啶脲基壳聚糖季铵盐及其制备方法和应用 |
CN108102116A (zh) * | 2018-01-25 | 2018-06-01 | 南京中医药大学 | 蛇床子素壳聚糖衍生物胶束及其制备方法和应用 |
CN112999151B (zh) * | 2019-12-19 | 2024-03-19 | 鲁南制药集团股份有限公司 | 一种口服用紫杉醇复合胶束 |
CN111116774A (zh) * | 2019-12-26 | 2020-05-08 | 广州振清环保技术有限公司 | 单6-氧-对苯乙烯磺酰-壳聚糖酯及其制备方法 |
-
2003
- 2003-03-14 CN CNB031129811A patent/CN1269844C/zh not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108273039A (zh) * | 2015-12-16 | 2018-07-13 | 新乡医学院第附属医院 | 一种治疗溶血性贫血的药物组合物及其应用 |
CN108273039B (zh) * | 2015-12-16 | 2021-04-30 | 新乡医学院第一附属医院 | 一种治疗溶血性贫血的药物组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1439655A (zh) | 2003-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Huo et al. | Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles | |
Parodi et al. | Nanomedicine for increasing the oral bioavailability of cancer treatments | |
EP3372226B1 (en) | Targeted hydrophobic anti-tumour drug nanoformulation and preparation method thereof | |
CN1269844C (zh) | 壳聚糖衍生物及其制备方法与在制药中的应用 | |
Gao et al. | Rapid and efficient crossing blood-brain barrier: hydrophobic drug delivery system based on propionylated amylose helix nanoclusters | |
CN102114246B (zh) | 生物体病灶部位特异性释药的两亲性多糖衍生物载体及其药学组合物的制备和应用 | |
Wang et al. | Functionalization of alkyne-terminated thermally hydrocarbonized porous silicon nanoparticles with targeting peptides and antifouling polymers: effect on the human plasma protein adsorption | |
CN100341900C (zh) | 季铵化壳聚糖衍生物、其制备方法及含其的药物制剂 | |
CN104415338A (zh) | 主动靶向型抗肿瘤药物及其制备方法 | |
CN108473538A (zh) | Sstr靶向缀合物及其颗粒和制剂 | |
Periyasamy et al. | Nanomaterials for the local and targeted delivery of osteoarthritis drugs | |
JP2018145115A (ja) | 高分子複合体 | |
CN105476975A (zh) | 主动靶向型抗脑肿瘤药物及其制备方法 | |
CN1840198A (zh) | 一种药物增溶载体及其制备方法和应用 | |
CN1503679A (zh) | 形成自聚集体的抗癌药-脱乙酰壳多糖复合体以及其制备方法 | |
Zhu et al. | Design of disintegrable nanoassemblies to release multiple small-sized nanoparticles | |
Zupancich et al. | Synthesis and self-assembly of RGD-functionalized PEO-PB amphiphiles | |
CN101474183B (zh) | 靶向性抗肿瘤药氯化两面针碱复合物的制备方法、其产品及含有该产品的注射剂 | |
CN101066461A (zh) | 细胞核靶向壳寡糖-脂肪酸嫁接物载药胶团的应用 | |
JP6772282B2 (ja) | 抗癌薬の新規ナノ製剤及びその製造方法 | |
CN1833633A (zh) | 一种可透血脑屏障的脂质体和以该脂质体为载体的药物组合物及其制备方法 | |
US9018156B2 (en) | Organic nanotube having hydrophobized inner surface, and encapsulated medicinal agent prepared using the nanotube | |
CN102924625B (zh) | 主动肿瘤靶向壳聚糖衍生物及其制备方法和用途 | |
CN105769821B (zh) | 他克莫司自组装聚合物纳米粒给药系统及其制备方法 | |
CN113648405B (zh) | 一种口服重组幽门螺杆菌蛋白疫苗纳米粒及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: JIANGSU HENGRUI MEDICINE CO., LTD. Effective date: 20050708 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050708 Address after: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24 Applicant after: China Pharmaceutical University Address before: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24 Applicant before: China Pharmaceutical University Co-applicant before: Hengrui Medicine Co., Ltd., Jiangsu Prov. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: NANJING YADONG QITIAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHINA PHARMACY UNIVERSITY Effective date: 20071116 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20071116 Address after: 211511 Taiwan Industry Park, Liuhe District, Nanjing Patentee after: Nanjing East Sunscreen Pharmaceutical Co.,Ltd. Address before: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24 Patentee before: China Pharmaceutical University |
|
ASS | Succession or assignment of patent right |
Owner name: EDDINGPHARM(CHINA) CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20100427 Address after: 211511 Taiwan Industry Park, Liuhe District, Nanjing Patentee after: Nanjing East Sunscreen Pharmaceutical Co.,Ltd. Patentee after: Eddingpharm (Chinese) Co. Ltd. Address before: 211511 Taiwan Industry Park, Liuhe District, Nanjing Patentee before: Nanjing East Sunscreen Pharmaceutical Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060816 Termination date: 20160314 |
|
CF01 | Termination of patent right due to non-payment of annual fee |